Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. Karyopharm Therapeutics shares fell over 21% amid concerns about share dilution from issuing new restricted stock units. Other firms like Privia Health Group and Avanos Medical also experienced notable losses following disappointing financial results and strategic changes. These events highlight how company decisions can quickly impact stock valuations.
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
Bitcoin options market data reveals a bullish shift as call options dominate 65.27% of open interest, signaling strong trader confidence in price gains. Open interest rose to nearly $32 billion with $3 billion in daily volume, indicating active parti...
Vessel traffic through the Strait of Hormuz has sharply declined by 66% following the US blockade initiated last week amid escalating US-Iran conflicts. Key shipping data shows tanker and gas carrier crossings fell from 90 to 30 in one week, reflecti...
BlackBerry is experiencing a strong turnaround with Q1 FY2027 revenues rising 26% year-over-year to $152.9 million, led by growth in its QNX and Secure Communications segments. The company also reported margin expansion and beat expectations on both ...
Strategy Inc. reports its bitcoin reserve can cover 31 years of dividend payments, while its U.S. dollar reserve provides 1.8 years of near-term dividend coverage. The company’s cash reserve has grown to $3.225 billion, strengthening its liquidity an...
